AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3931943
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine infusion (0.1 microgram/kg/min)
Trial: 27368012
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (double-low protocol): 100 kVp tube voltage with 40% ASIR, iodixanol at 270 mg I/mL
Trial: 27368012
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 120 kVp tube voltage with filtered back projection (FBP), iodixanol at 270 mg I/mL
Trial: 27368012
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 120 kVp tube voltage with FBP, ioversol at 350 mg I/mL
Trial: 22972216
Drug: Empowerment intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empowerment intervention (10 weekly hour-long sessions including group education and group discussion)
Trial: 17501758
Drug: pegIFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFN plus RBV (1000 mg if body weight <75 kg and 1200 mg if >75 kg)
Trial: 17501758
Drug: pegIFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFN plus RBV (1000-1200 mg/day)
Trial: 17501758
Drug: pegIFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegIFN plus RBV (800 mg/day)
Trial: 11448801
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid/day
Trial: 7920074
Drug: H2-blocker therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2-blocker therapy with famotidine
Trial: 7920074
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with bismuth, amoxicillin, and metronidazole
Trial: 31567725
Drug: Extended prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended prophylactic nevirapine given daily from 6 weeks to 6 months
Trial: 31567725
Drug: Maternal antiretroviral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal antiretroviral therapy exposure
Trial: 27513639
Drug: Periosteal Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periosteal Stimulation Therapy (PST) with boosters and home exercise program
Trial: 25053182
Drug: Levosimendan (LS)
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (LS) therapy
Trial: 19535709
Drug: Personalized video‐assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized video‐assisted oral debriefing
Trial: 9642436
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl at 40, 60, or 120 mg bid
Trial: 1783533
Drug: Naloxone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (5 mg/kg loading dose over 10 minutes followed by 24-hour infusion at 3.5 mg/kg/h)
Trial: 24016810
Drug: Licensed trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed trivalent influenza vaccine (TIV)
Trial: 24016810
Drug: Investigational trivalent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational trivalent influenza vaccine (TIV)
Trial: 18264759
Drug: Letrozole (prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (prolonged treatment beyond 3 months)
Trial: 14730252
Drug: Clopidogrel in
RxNorm normalized name: Product containing clopidogrel in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel in combination with ASA
Trial: 14730252
Drug: Long-term clopidogrel
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term clopidogrel therapy
Trial: 14730252
Drug: Extended clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended clopidogrel therapy
Trial: 11072147
Drug: PTA +
RxNorm normalized name: Achillea ptarmica whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTA + BT (intraarterial high-dose-rate brachytherapy)
Trial: 2805828
Drug: 4 percent
RxNorm normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 percent lidocaine (Xylocaine 4 percent topical)
Trial: 2805828
Drug: 4 percent
RxNorm normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 percent lidocaine (commercial preparation)
Trial: 2805828
Drug: 4 percent
RxNorm normalized name: LIDOCAINE 4 g in 100 g TOPICAL PATCH [Lidocaine 4 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 percent preservative-free lidocaine solution
Trial: 21256803
Drug: ramelteon 8
RxNorm normalized name: ramelteon 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramelteon 8 mg
Trial: 12762347
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone over 24 hours
Trial: 11061530
Drug: Daily rGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rGH injections (Group A)
Trial: 11061530
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly rGH injections (Group B)
Trial: 11061530
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after 6 months of therapy
Trial: 11061530
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after 12 months of therapy
Trial: 8598549
Drug: RRR-alpha-tocopheryl acetate
RxNorm normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopheryl acetate (TA) 0 mg/d
Trial: 8598549
Drug: RRR-alpha-tocopheryl acetate
RxNorm normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopheryl acetate (TA) 100 mg/d
Trial: 8598549
Drug: RRR-alpha-tocopheryl acetate
RxNorm normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopheryl acetate (TA) 200 mg/d
Trial: 8598549
Drug: RRR-alpha-tocopheryl acetate
RxNorm normalized name: RRR-alpha-tocopheryl acetate
DrugBank: D-alpha-Tocopherol acetate (DB14002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopheryl acetate (TA) 400 mg/d
Trial: 4555773
Drug: A2/England/1/1966 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2/England/1/1966 vaccine (300 CCA)
Trial: 4555773
Drug: A/equine 2/Miami/1963
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/equine 2/Miami/1963 vaccine (300 CCA)
Trial: 26049123
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (60 mg/m²) and carboplatin (AUC 2.7) with prophylactic G-CSF (filgrastim) given on day 5 (and if needed on day 6)
Trial: 26049123
Drug: Historical data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical data without routine use of prophylactic G-CSF
Trial: 16769471
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone treatment
Trial: 12897375
Drug: Euthyroid patients
RxNorm normalized name: Renthyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyroid patients with positive thyroid antibody titers
Trial: 9129557
Drug: Regular-strength grapefruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-strength grapefruit juice with 60 mg terfenadine
Trial: 9129557
Drug: Double-strength grapefruit
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-strength grapefruit juice with 60 mg terfenadine
Trial: 9129557
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 60 mg terfenadine
Trial: 29356576
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Alpha-Lipoic Acid (ALA) per day for 1 month before surgery and for 2 months afterward
Trial: 1828550
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate 10 mg daily (days 12-25)
Trial: 6313501
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g guar gum
Trial: 31380663
Drug: Borrowers showing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Borrowers showing greater positive arousal (e.g., excitement) in profile photos
Trial: 28415937
Drug: Heparin saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin saline (50 IU/ml, 3 ml)
Trial: 28415937
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (3 ml)
Trial: 24390887
Drug: Enhanced feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced feedback (weight, BMI, blood pressure, homeostatic insulin resistance, nuclear magnetic resonance lipoprotein profiles at 2, 4, 7, and 10 months)
Trial: 19276983
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcoholic red wine (8.1±0.9 dl)
Trial: 17445412
Drug: Intravenous Acehytisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acehytisine Hydrochloride (AHH) 4 mg/kg, iv.
Trial: 17445412
Drug: Propafenone (PRO)
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propafenone (PRO) 1 mg/kg, iv.
Trial: 17445412
Drug: Intravenous Acehytisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acehytisine Hydrochloride (AHH)
Trial: 11176735
Drug: Sibutramine hydrochloride
RxNorm normalized name: Sibutramine Hydrochloride
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine hydrochloride alone (drug-alone group)
Trial: 11176735
Drug: Sibutramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine plus group lifestyle modification (drug-plus-lifestyle group)
Trial: 11176735
Drug: Sibutramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine plus portion-controlled diet (combined treatment group)
Trial: 11176735
Drug: Drug-alone group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-alone group
Trial: 11176735
Drug: Drug-plus-lifestyle and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-plus-lifestyle and combined treatment groups
Trial: 9608581
Drug: Yohimbine (α2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (α2 antagonist)
Trial: 8140046
Drug: Sandimmune (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune (300 mg) under fasting conditions
Trial: 8140046
Drug: Sandimmune (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune (300 mg) after a high-fat meal
Trial: 8140046
Drug: Sandimmune Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune Neoral (180 mg) under fasting conditions
Trial: 8140046
Drug: Sandimmune Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune Neoral (180 mg) after a high-fat meal
Trial: 3132732
Drug: Helium ion
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helium ion radiation therapy
Trial: 28405683
Drug: Bladder intracavitary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder intracavitary hyperthermic perfusion chemotherapy (BHPC)
Trial: 28405683
Drug: Intravesical chemotherapy
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical chemotherapy alone
Trial: 20967571
Drug: Exercise support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise support therapy (ST)
Trial: 20967571
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (PT)
Trial: 16498858
Drug: Topical cetirizine‐dinitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cetirizine‐dinitrate (2.44 mg per nasal cavity) delivered via nasal spray device
Trial: 16498858
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline lavage before treatment)
Trial: 10930904
Drug: RAC400 (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC400 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 200 mg b.d.)
Trial: 10930904
Drug: RAC800 (rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC800 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 400 mg b.d.)
Trial: 1628727
Drug: Inhaled bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bradykinin
Trial: 8519379
Drug: Inhaled kallidin
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled kallidin
Trial: 8519379
Drug: Inhaled [desArg9]-bradykinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled [desArg9]-bradykinin
Trial: 8519379
Drug: Inhaled kallidin
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled kallidin after bradykinin challenge
Trial: 8519379
Drug: Inhaled bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bradykinin after kallidin challenge
Trial: 8519379
Drug: Repeated exposures
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated exposures with inhaled [desArg9]-bradykinin
Trial: 2958234
Drug: Commercial cream
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial cream for glass fibre itching
Trial: 2958234
Drug: Fatty ointment
RxNorm normalized name: FATTY OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty ointment
Trial: 2958234
Drug: Cream-ointment
RxNorm normalized name: Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream-ointment
Trial: 15717460
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% with fentanyl 2.2 microg/ml
Trial: 12707429
Drug: Pregabalin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (600 mg/day for creatinine clearance > 60 mL/min or 300 mg/day for creatinine clearance 30 to 60 mL/min)
Trial: 1987228
Drug: Calcitonin gene-related
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin gene-related peptide infusion (16 ng/kg per min)
Trial: 1987228
Drug: Calcitonin gene-related
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin gene-related peptide infusion
Trial: 6342165
Drug: SAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAC plus 1 g ascorbic acid (Redoxon) daily for 6 months
Trial: 6342165
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1 g intravenous injection)
Trial: 29563289
Drug: Maraviroc monotherapy
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc monotherapy
Trial: 26772807
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues (AI) - insulin detemir and insulin aspart
Trial: 26772807
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (HI) - NPH-insulin and regular HI
Trial: 24910870
Drug: Retinyl retinoate-loaded
RxNorm normalized name: retinyl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl retinoate-loaded dissolving microneedle patches
Trial: 24910870
Drug: Ascorbic acid-loaded
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid-loaded dissolving microneedle patches
Trial: 27774730
Drug: Conventional thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrice weekly hemodialysis
Trial: 12393661
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-1 receptor antagonist (IL-1Ra)
Trial: 8657828
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol [Estraderm TTS (ETTS) 50 micrograms, applied twice weekly]
Trial: 358427
Drug: Carbuterol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbuterol (2.0 mg tablets)
Trial: 358427
Drug: Fenoterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (2.5 mg tablets)
Trial: 358427
Drug: Hexoprenaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoprenaline (1 mg tablets)
Trial: 358427
Drug: Carbuterol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbuterol (200 mg aerosol)
Trial: 358427
Drug: Fenoterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (400 mg aerosol)
Trial: 358427
Drug: Hexoprenaline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoprenaline (200 mg aerosol)
Trial: 25668261
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous gluconate (37.5 mg of elemental iron) daily for 24 weeks (168 days)
Trial: 7717236
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.6 mg/kg
Trial: 19414968
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.6 mg/kg plus nitrous oxide-oxygen inhalation
Trial: 15897444
Drug: Antithrombotic agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents alone
Trial: 7617495
Drug: APF gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF gel and foam
Trial: 2533187
Drug: COP 1
RxNorm normalized name: COP 1
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COP 1 treatment
Trial: 31174403
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 1000 mg calcium and 800 IU cholecalciferol
Trial: 31174403
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 1000 mg calcium and 800 IU cholecalciferol with an additional 1 ml liquid cholecalciferol (50,000 IU) monthly
Trial: 23588240
Drug: True-elimination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True-elimination diet + topical nifedipine and lidocaine
Trial: 23588240
Drug: Sham-elimination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-elimination diet + topical nifedipine and lidocaine
Trial: 21439030
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (n = 16)
Trial: 20133266
Drug: fosamprenavir/ritonavir 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir/ritonavir 1400 mg/100 mg once daily
Trial: 20133266
Drug: fosamprenavir/ritonavir 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir/ritonavir 700 mg/100 mg twice daily
Trial: 10360370
Drug: Idarubicin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin (8 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Trial: 10360370
Drug: Mitoxantrone (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (7 mg/m2/day on days 1, 3, and 5) combined with VP-16 (100 mg/m2/day on days 1 to 3) and cytarabine (100 mg/m2/day on days 1 to 7)
Trial: 10360370
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg/day) following induction
Trial: 10360370
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF following induction
Trial: 8706174
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Chongqing Glaxo Limited (Group A)
Trial: 8706174
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate nasal spray (BDNS) manufactured in Glaxo UK (Group B)
Trial: 6122463
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg slow release oxprenolol